Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Pneumocystis Infection - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 29 | Code: MRS - 18523


Global Markets Directs, Pneumocystis Infection Pipeline Review, H2 2014, provides an overview of the Pneumocystis Infections therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pneumocystis Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pneumocystis Infection and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Pneumocystis Infection
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Pneumocystis Infection and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Pneumocystis Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Pneumocystis Infection pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Pneumocystis Infection
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Pneumocystis Infection pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 3
List of Figures 3

Introduction 4
Global Markets Direct Report Coverage 4
Pneumocystis Infection Overview 5
Therapeutics Development 6
Pipeline Products for Pneumocystis Infection - Overview 6
Pipeline Products for Pneumocystis Infection - Comparative Analysis 7
Pneumocystis Infection - Therapeutics under Development by Companies 8
Pneumocystis Infection - Therapeutics under Investigation by Universities/Institutes 9
Pneumocystis Infection - Pipeline Products Glance 10
Early Stage Products 10
Pneumocystis Infection - Products under Development by Companies 11
Pneumocystis Infection - Products under Investigation by Universities/Institutes 12
Pneumocystis Infection - Companies Involved in Therapeutics Development 13
BioDiem Ltd 13
Pneumocystis Infection - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Drug Profiles 18
BDM-I - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody for Pneumocystis Infection - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MVX-504 - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MVX-505 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
pneumocystis vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Pneumocystis Infection - Recent Pipeline Updates 24
Pneumocystis Infection - Discontinued Products 26
Pneumocystis Infection - Product Development Milestones 27
Featured News & Press Releases 27
May 10, 2013: BioDiem's BDM-I Progresses To Preclinical Animal Studies In NIH Research Program As Fungal Infection Treatment 27
Jun 04, 2012: MiniVaxs Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load 27

Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables

Number of Products under Development for Pneumocystis Infection, H2 2014 6
Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Number of Products under Investigation by Universities/Institutes, H2 2014 9
Comparative Analysis by Early Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Products under Investigation by Universities/Institutes, H2 2014 12
Pneumocystis Infection - Pipeline by BioDiem Ltd, H2 2014 13
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Stage and Route of Administration, H2 2014 15
Number of Products by Stage and Molecule Type, H2 2014 17
Pneumocystis Infection Therapeutics - Recent Pipeline Updates, H2 2014 24
Pneumocystis Infection - Discontinued Products, H2 2014 26

List of Figures

Number of Products under Development for Pneumocystis Infection, H2 2014 6
Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Comparative Analysis by Early Stage Products, H2 2014 10
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Top 10 Molecule Types, H2 2014 16
Number of Products by Stage and Top 10 Molecule Types, H2 2014 16

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing